Results 131 to 140 of about 2,693 (166)
Some of the next articles are maybe not open access.
New Perspectives on Antimicrobial Agents: Imipenem-Relebactam
Antimicrobial Agents and Chemotherapy, 2022Imipenem (IMI)/cilastatin/relebactam (REL) (I/R) is a novel β-lactam/β-lactamase inhibitor combination with expanded microbiologic activity against carbapenem-resistant non- Morganellaceae Enterobacterales (CR-NME) and difficult-to-treat (DTR) Pseudomonas aeruginosa .
J. Nicholas O’Donnell +1 more
openaire +2 more sources
Rapid detection of imipenem/relebactam susceptibility/resistance in Enterobacterales
Clinical Microbiology and Infection, 2023The treatment options for infections caused by carbapenem-resistant Enterobacterales are scarce and the development of new antibiotics is an urgent necessity. Imipenem/relebactam (IPR) has been recently introduced for treating severe infections related to multidrug-resistant bacteria.
Maxime, Bouvier +4 more
openaire +2 more sources
Expert Opinion on Pharmacotherapy, 2020
The addition of the β-lactamase inhibitor relebactam to imipenem restores the antibacterial activity against the majority of multidrug resistant Gram-negative bacteria. Complicated urinary tract infections (UTIs) are predominantly caused by Gram-negative uropathogens.
S.G. Kuiper +3 more
openaire +2 more sources
The addition of the β-lactamase inhibitor relebactam to imipenem restores the antibacterial activity against the majority of multidrug resistant Gram-negative bacteria. Complicated urinary tract infections (UTIs) are predominantly caused by Gram-negative uropathogens.
S.G. Kuiper +3 more
openaire +2 more sources
Clinical Pharmacokinetics and Pharmacodynamics of Imipenem–Cilastatin/Relebactam Combination Therapy
Clinical Pharmacokinetics, 2020On 16 July, 2019, the US Food and Drug Administration approved imipenem-cilastatin/relebactam (Recarbrio™) for the treatment of adults with complicated urinary tract infections and complicated intra-abdominal infections. This decision was based on substantial clinical and pre-clinical data, including rigorous pharmacokinetic and pharmacodynamic work ...
openaire +2 more sources
Thorough QTc Study of a Single Supratherapeutic Dose of Relebactam in Healthy Participants
Clinical Pharmacology in Drug Development, 2020AbstractThe effects of supratherapeutic doses of intravenous (IV) relebactam on duration of ventricular depolarization and subsequent repolarization were assessed in a thorough QT/corrected QT study. This was a single‐dose, double‐blind (relebactam only), randomized, placebo‐ and positive‐controlled, 3‐period, balanced crossover study in healthy ...
Keith, Boundy +8 more
openaire +2 more sources
Chemical Communications, 2022
The first catalytic asymmetric total synthesis of marketed DBO β-lactamase inhibitors avibactam and relebactam has been achievedviaa Rh-catalysed asymmetric hydrogenation along with multiple flow procedures.
Zhi Yang +5 more
openaire +2 more sources
The first catalytic asymmetric total synthesis of marketed DBO β-lactamase inhibitors avibactam and relebactam has been achievedviaa Rh-catalysed asymmetric hydrogenation along with multiple flow procedures.
Zhi Yang +5 more
openaire +2 more sources
Imipenem-cilastatin and imipenem-relebactam
2017The carbapenems are a group of bicyclic beta-lactam compounds with a common carbapenem nucleus. Imipenem (N-formimidoyl-thienamycin: C12H17N3O4S; average molecular weight: 299.3460) is one of these, and it has substantial activity against both aerobic and anaerobic bacteria, including many (but not all) beta-lactamase-producing strains.
Hayashi, Yoshiro, Paterson, David L.
openaire +2 more sources
Rapid detection of imipenem/relebactam susceptibility/resistance in Pseudomonas aeruginosa
Diagnostic Microbiology and Infectious DiseaseImipenem-relebactam (IPR) has been reported to exhibit a good activity against non-metallo-ß-lactamase carbapenem-resistant Pseudomonas aeruginosa (CRPA), and the rapid detection of susceptibility/resistance to this new therapeutic alternative may be crucial.
Maxime Bouvier +3 more
openaire +2 more sources
Journal of Antimicrobial Chemotherapy
Abstract Background Extracorporeal membrane oxygenation (ECMO) is a life-saving modality but has the potential to alter the pharmacokinetics (PK) of antimicrobials. Imipenem/cilastatin/relebactam is an antibiotic with utility in treating certain multi-drug resistant Gram-negative infections.
Andrew J Fratoni +4 more
openaire +2 more sources
Abstract Background Extracorporeal membrane oxygenation (ECMO) is a life-saving modality but has the potential to alter the pharmacokinetics (PK) of antimicrobials. Imipenem/cilastatin/relebactam is an antibiotic with utility in treating certain multi-drug resistant Gram-negative infections.
Andrew J Fratoni +4 more
openaire +2 more sources